Trial Information

Summary: Meningitis Vaccine Study

What is meningococcal disease?

Meningococcal disease is a serious bacterial infection. It can cause meningitis - a severe infection of the brain and spinal cord. It can also lead to sepsis - a dangerous blood infection.

Every year in the US approximately 2,500 people are infected with meningococcus, the leading cause of bacterial meningitis. The highest risk of Meningococcal disease occurs in infants less than 1 year of age. About 1 in 10 people who get meningococcal disease do not survive.

The purpose of this clinical research study is to assess the safety of the meningococcal vaccine and to measure the immune response to the vaccine when compared to immune response of the licensed Menactra(TM) vaccine (for meningitis) in healthy children between 2 and 10 years of age.

Your healthy child may qualify for this study if he/she:

• Is approximately 2-10 years old
• Has received complete primary vaccinations with recommended licensed vaccines

If your child qualifies for this study, you will receive at no cost:

• Study vaccination(s)
• Study-related office visits and physical assessments.

If your child is enrolled in the trial, you will receive compensation for time and travel.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.